Geoffrey Lim Uy MD

Oncology•Saint Louis, MO

Hematologic Oncology

Professor of Medicine, Washington University School of Medicine

Join to View Full Profile

4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 314-454-8304
Fax+1 314-454-5902

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2003 - 2007
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

IL State Medical License 2020 - 2026
MO State Medical License 2002 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
Active, not recruiting
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Sep 01
ACTIVE_NOT_RECRUITING
PHASE2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
ACTIVE_NOT_RECRUITING
PHASE2
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia Start of enrollment: 2008 Jun 01
Active, not recruiting
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 1, Phase 2
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) Start of enrollment: 2010 May 01
Terminated
Phase 1
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2012 May 14
Completed
Phase 1, Phase 2
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Apr 01
Completed
Phase 2
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia Start of enrollment: 2011 Jul 01
Completed
Early Phase 1
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation Start of enrollment: 2013 Feb 25
Completed
Phase 1
Geriatric Assessments in Senior Adults With Multiple Myeloma Start of enrollment: 2012 Sep 01
Completed
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Start of enrollment: 2013 Apr 15
Terminated
Phase 1, Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
ACTIVE_NOT_RECRUITING
PHASE3
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
COMPLETED
PHASE3
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Jun 09
Terminated
Phase 1, Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML Start of enrollment: 2014 Oct 01
Withdrawn
Phase 1
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2015 Jun 16
Completed
Phase 1, Phase 2
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies Start of enrollment: 2016 Mar 31
Completed
Phase 2
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Start of enrollment: 2016 Dec 02
Terminated
Phase 2
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2018 Oct 15
TERMINATED
PHASE3
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy Start of enrollment: 2019 Mar 28
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Start of enrollment: 2023 Oct 10
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.
Ramzi Abboud, Mark A Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao
Blood. 2025-03-27
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
Nadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, Daelynn R Buelow, Shelley Orwick
Leukemia. 2025-03-01
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
Cancer. 2025-02-15

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

$10.8 Million Grant Supports Cutting-Edge Leukemia ResearchDecember 16th, 2024
World Leaders in Ending Blood CancerNovember 14th, 2024
You Make the Call: How Would You Treat This Transplant-Ineligible Patient with Ph+ ALL?September 30th, 2021
Join now to see all

Grant Support

Clinician Scientist in LeukemiaWASHINGTON UNIVERSITY2023–2028
Clinician Scientist in LeukemiaWASHINGTON UNIVERSITY2023–2028
Targeting Leukemia Stromal Interactions In AMLNational Cancer Institute2009–2011